To develop newer and more effective chemopreventive agents for
skin cancer, we assessed the effect of
honokiol, a
phytochemical from the Magnolia plant, on ultraviolet (UV) radiation-induced skin
tumorigenesis using the SKH-1 hairless mouse model. Topical treatment of mice with
honokiol in a hydrophilic cream-based topical formulation before or after UVB (180 mJ/cm(2)) irradiation resulted in a significant protection against photocarcinogenesis in terms of
tumor multiplicity (28-60%, P < 0.05 to <0.001) and
tumor volume per
tumor-bearing mouse (33-80%, P < 0.05 to 0.001, n = 20).
Honokiol also inhibited and delayed the malignant progression of
papillomas to
carcinomas. To investigate the in vivo molecular targets of
honokiol efficacy,
tumors and
tumor-uninvolved skin samples from the
tumor-bearing mice were analyzed for inflammatory mediators, cell cycle regulators and survival signals using immunostaining, western blotting and
enzyme-linked
immunosorbent assay. Treatment with
honokiol significantly inhibited UVB-induced expression of
cyclooxygenase-2,
prostaglandin E(2) (P < 0.001),
proliferating cell nuclear antigen and proinflammatory
cytokines, such as
tumor necrosis factor-α (P < 0.001),
interleukin (IL)-1β (P < 0.01) and
IL-6 (P < 0.001) in the skin as well as in skin
tumors. Western blot analysis revealed that
honokiol: (i) inhibited the levels of
cyclins D1, D2 and E and associated
cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of
phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin
tumors. Together, our results indicate that
honokiol holds promise for the prevention of UVB-induced
skin cancer by targeting inflammatory mediators, cell cycle regulators and cell survival signals in UVB-exposed skin.